@jakeperson
@biovail
RE: what good are the 2c-x's
Back in the 80's there was some research done with 2c-t-2 and 2c-t-7 as a more effective tool in psychotherapy than MDMA because the analytical edge they give coupled with empathogenic qualities surpassed MDMA in being able to not only come to terms with trauma, but allowed them to engage with traumatic events and integrate them better. Check it:
“Preliminary Results with New Psychoactive Agents 2C-T-2 AND 2C-T-7”.
http://www.erowid.org/references/refs_view.php?ID=1198
Abstract
Preliminary test reports of two new phenethylamines, 2C-T-2 and 2C-T-7, which show promise as facilitators in psychotherapy, are compared to virgin use of MDMA (1). The purpose of the tests was to determine whether there were sufficient useful properties of the drugs to warrant further study, without contra-indicating side-effects. Drugs were administered in a friendly, supportive atmosphere with serene natural surroundings. Participants were requested to fill out a one-page questionnaire within a few days following the experience rating physical symptoms and various areas of functioning, and provide pertinent comments. Objectionable physical symptoms were minimal, and the majority experienced improvement in functioning in such areas as clarity of thought, flow of insights, communication with others, visual perception, energy level, feelings of well-being, and expanded dimensions of thought. Most found the experience valuable, and a large majority (41 to 4) would repeat the experience.
The objectives of the study were twofold. First, to determine whether the substances being explored show any potential usefulness for facilitating psychotherapy, for use as learning tools with regard to self, relationships, or the nature of reality, or as enhancers of functions like intuition, creativity, and clarity and range of thought. And second, whether they are free of readily noticeable, undesirable side effects. We hope through this preliminary study to stimulate further scientific research into these interesting compounds and to alert future researchers to possible contraindications.
~It actually makes me sad that MAPS does virtually no advocacy for the work of Shulgin and Nichols; although, it should be understood that MAPS is coming from a particular perspective, very in line with the medical marijuana movement, advocating the use of psychedelics as psychospiritual tools to treat psychiatric issues. Shulgin & Nichols' work is situated within the gigantic maw of pharmaceutical research and development. Perhaps the best way to present psychedelics as a legit field of study would be to look at them from a cognitive neuroscience perspective, looking at the neurophysiology of perception and differentiating this research from clinical applications in medicine and psychotherapy.
There's some research headed this way already, Shulgin wanted to study the metabolism of psychedelics in the body as to highlight particular receptor systems, so he radio-labeled 2c-I and DOI. Now that Shulgin's compounds are more difficult to work with because of politics, Nichols creates the NBOMe derrivatives and radio-labels 25i-NBOMe to investigate the human receptome. Most of the time though, these studies are done from a clinical psychiatric perspective, trying to develop new generations of anti-depressants, or ways to chemically characterize disorders like "schizophrenia" so as to chemically reverse engineer them.
The big difference though between Nichols and Shulgin is that Shulgin designed his compounds with the intent that they would be tested in humans. Sasha even went so far as to say it's unethical for a doctor to administer a medicine to a patient that he hadn't tried on himself and that
it's impossible to assess a rat for changes in self-worth and this is why studying what psychedelics do subjectively in humans is imperative. Nichols, on the other hand, finds rat studies a valid way to assess receptor activity, and takes an ambivalent approach to the way his research is appropriated by the recreational community --except in times where he stops to make public service announcements in the media
disavowing his research being hijacked by legal high makers. But it's important to note that Nichols isn't overtly developing compounds to be tested in humans and several compounds he developed are in fact NOT safe for human consumption and there's been a few fatalities with compounds Nichols developed .
What seems to be the problem more generally though is the way in which the next-generation stimulants (subsituted cathinones) and synthetic cannabinoids industries seem to be the biggest economies that are driving the R&D in the RC world and large amounts of media attention focusing on accidents/freakouts/disasters due in part to irresponsibility, and also in part because there's not enough resources on how to safely use/dose, and also the ethically questionable trend in legal high marketing that obscures the identity of the drugs you're getting) end up getting stuff like MDAI grouped in a ban with 2c-x's along side cannabinoids and cathinones in the US. How did that happen? I think we need to be better representatives of drug culture and start educating people more generally about what it is we're doing and how to party proper.
The recreational scene. The spirituality/therapy scenes. The neuro-perceptual scene. these should all be seen as legit areas of research and we need to start initiating on-the-ground as well as on-the-web conversations about this if we want this to change.